• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pulmatrix Inc.

Pulmatrix completes patient dosing for inhaled migraine treatment

September 26, 2022 By Sean Whooley

Pulmatrix iSperse migraine therapy

Pulmatrix (Nasdaq:PULM) announced today that all subjects completed dosing in a trial of its orally inhaled migraine treatment. Lexington, Massachusetts-based Pulmatrix is evaluating PUR3100 in a Phase 1 trial using the patented iSperse technology. All subjects completed dosing of the novel orally inhaled formulation of dihydroergotamine (DHE). The company expects Phase 1 data in the […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Pulmatrix Inc.

Pulmatrix completes $40M offering, updates product pipeline timetable

March 4, 2021 By Sean Whooley

pulmatrix

Pulmatrix (NSDQ:PULM) announced today that it completed an offering with gross proceeds of approximately $40 million. Lexington, Mass.-based Pulmatrix said in a news release that it completed the registered direct offering to extend the company’s cash runway. Now, the company has additional financing to help fully fund data readouts across its development pipeline, which includes a […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Pharmaceuticals, Research & Development Tagged With: Pulmatrix Inc.

Pulmatrix doses first patient in Pulmazole trial

September 19, 2019 By Sean Whooley

Pulmatrix

Pulmatrix (NSDQ:PULM) said yesterday that it dosed the first patient in its Phase II trial of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis asthmatics. The 64-patient study is a randomized, double-blinded, placebo-controlled trial to evaluate the safety and efficacy of three dose levels of the anti-fungal drug itraconazole formulation Pulmazole. The multi-center, four-arm trial will […]

Filed Under: Clinical Trials, Featured, Respiratory Tagged With: Pulmatrix Inc.

Pulmatrix, Cipla Technologies ink deal for inhaled anti-fungal

April 16, 2019 By Fink Densford

Pulmatrix

Pulmatrix (NSDQ:PULM) said yesterday that it inked a deal with Cipla to co-develop and commercialize an inhaled iSperse formulation of the anti-fungal drug itraconazole, intended for treating allergic bronchopulmonary aspergillosis in asthma patients. Lexington, Mass.-based Pulmatrix said that it in the deal, Cipla’s Cipla Tech subsidiary will make an upfront payment of $22 million to Pulmatrix […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: cipla, Pulmatrix Inc.

Pulmatrix prices $14m offering

April 4, 2019 By Fink Densford

Pulmatrix

Pulmatrix (NSDQ:PULM) yesterday priced an upcoming offering looking to raise approximately $14.4 million. The Lexington, Mass.-based company said that it plans to float approximately 10.7 million units at a price of $1.35 per unit. Each unit in the offering is comprised of one share of common stock and one warrant to purchase a single share of […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix announces 1-for-10 reverse split, $1m offering

February 8, 2019 By Fink Densford

Pulmatrix

Pulmatrix (NSDQ:PULM) this week announced both a 1-for-10 reverse split of its stock and the closing of an offering which brought in approximately $905,000. On Tuesday, the Lexington, Mass.-based company said that it initiated a 1-for-10 reverse split of its common stock, putting a single share in the hands of each shareholder for each 10 shares they […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy

February 7, 2019 By Sarah Faulkner

Pulmatrix

Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma. The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix raises $3m in offering

November 30, 2018 By Sarah Faulkner

Pulmatrix

Pulmatrix (NSDQ:PULM) said this week that it inked a deal with an institutional investor to sell 9,375,000 shares of common stock at 32¢ apiece. The Lexington, Mass.-based company expects to reel in $3 million in total gross proceeds from the offering. Pulmatrix also agreed to issue unregistered warrants to the same investor in a private placement […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy

July 17, 2018 By Sarah Faulkner

Pulmatrix

Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma. The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix touts Ph1 data for inhaled COPD therapy

June 13, 2018 By Sarah Faulkner

Pulmatrix

Pulmatrix (NSDQ:PULM) touted data today from a dose-ranging Phase I trial of its once-daily inhaled therapy designed for people with chronic obstructive pulmonary disease. The company’s product is a reformulation of tiotropium bromide, the active component in Boehringer Ingelheim’s blockbuster drug, Spiriva. Pulmatrix used salt-based excipients and spray-drying techniques as part of its iSperse drug-delivery platform to […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS